Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q8NBN7
UPID:
RDH13_HUMAN
Alternative names:
Short chain dehydrogenase/reductase family 7C member 3
Alternative UPACC:
Q8NBN7; Q6UX79; Q96G88
Background:
Retinol dehydrogenase 13, also known as Short chain dehydrogenase/reductase family 7C member 3, plays a crucial role in the metabolism of retinoids, favoring NADP as a cofactor. It efficiently oxidizes all-trans-retinol and reduces all-trans-retinal, showcasing specificity towards retinoid substrates over steroids.
Therapeutic significance:
Understanding the role of Retinol dehydrogenase 13 could open doors to potential therapeutic strategies, particularly in disorders related to vitamin A metabolism and retinoid homeostasis.